CAMZYOS® (mavacamten) Patient Guide

Date of MHRA Approval: July 2023 Local Approval Number: 3500-GB-2200049 Date of Preparation: July 2023

🖑 Bristol Myers Squibb

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may experience. See www.mhra.gov.uk/yellowcard for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com.

IMPORTANT SAFETY INFORMATION FOR PATIENTS OF CHILDBEARING POTENTIAL

If you are of childbearing potential, please review the information below before you start treatment with mavacamten and keep this page for your reference.

Mavacamten and the risk of embryo-fetal toxicity (toxicity to an unborn baby)

Mavacamten must not be taken if you are pregnant or if you are of childbearing potential and are not using an effective method of contraception (birth control) as mavacamten may cause harm to an unborn baby.

If you are able to get pregnant, you will need a confirmed negative pregnancy test before you start taking mavacamten. You must use an effective method of contraception throughout treatment and for 6 months after your last dose of mavacamten. You should discuss with your doctor which method(s) of contraception is/are the most suitable for you.

Talk to your doctor if you are considering becoming pregnant. If you suspect you may be pregnant or are pregnant while receiving mavacamten, tell your prescriber or doctor **immediately**. Your prescriber or doctor will discuss your treatment options with you. This **Patient Guide** contains a **Patient Card**.

Carry this Patient Card with you at all times.

Tell any healthcare professional who sees you that you are taking mavacamten. The **Patient Card** contains information on the main risks of mavacamten and contact details of your prescriber.

CAMZYOS®▼(mavacamten) PATIENT CARD

Please ensure that you read the package leaflet for this medicine, which gives more information about mavacamten. If you have any further questions, talk to your prescriber, doctor or pharmacist.

WHAT ARE ECHOCARDIOGRAMS, AND WHY ARE THEY IMPORTANT?

Regular echocardiograms (also known as echos) will help your doctor evaluate how mavacamten affects your heart. An echo is a test that uses sound waves to create pictures of the heart. These tests allow your doctor to see how your heart is responding to treatment and make sure you are on the optimal dose. Based on the echo results, your doctor may increase, decrease or maintain your dose of mavacamten or pause or stop your treatment. Your first echo will be performed before starting mavacamten. Follow-up echos will be 4, 8 and 12 weeks after your first dose of mavacamten and then every 12 weeks afterwards.

You will also need to have echos as instructed by your doctor if your dose of mavacamten is changed or if the dose of another medicine you are taking is changed.

	╈
	×

It is important to schedule and attend echos as instructed by your prescriber. Set reminders on your phone or calendar to help you remember the date and time of your echos.

There are three main risks associated with treatment with mavacamten:

- Embryo-fetal toxicity (toxicity to an unborn baby) (please see page 3)
- Heart failure due to systolic dysfunction, a condition where the heart cannot pump enough blood to the body
- Increase in the amount of mavacamten in the body due to interactions with certain medicines and herbal supplements, which can make patients more likely to get side effects (some of which may be severe)

Other possible side effects related to mavacamten are outlined in the package leaflet.

Mavacamten and heart failure

Heart failure due to systolic dysfunction is a serious and sometimes fatal condition.

Tell your prescriber or doctor, or seek other medical attention **immediately** if you experience new or worsening symptoms of heart failure, including shortness of breath, chest pain, fatigue, a racing heart (palpitations), or leg swelling.

Tell your prescriber or doctor of any new or existing medical condition(s) you experience before and during treatment with mavacamten.

IMPORTANT SAFETY INFORMATION (continued)

Mavacamten and interactions

Some medicines, including those available over-the-counter, and some herbal supplements can affect the amount of mavacamten in your body and make it more likely for you to get side effects (some of which may be severe). Tell your prescriber, doctor or pharmacist about all the prescription medicines, over-the-counter medicines and herbal supplements you take, even if you do not take them every day. **Do not** start taking, stop taking or change the dose of any of your medicines or herbal supplements without talking to your prescriber, doctor or pharmacist.

Some examples of products that may affect how much mavacamten is in your body are shown in **Table 1**. Please note, these examples are a guide and are not considered a comprehensive list of all possible medicines that may fit this category. Intermittent use of products that might affect the levels of mavacamten in your body, including prescription and over-the-counter medicines, herbal supplements and grapefruit juice, is not recommended. Table 1: Examples of products that may affect mavacamten

Products	Condition treated		
Omeprazole, esomeprazole	Gastric ulcers and acid reflux		
Clarithromycin, rifampicin	Bacterial infections		
Verapamil, diltiazem	Heart conditions		
Fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole	Fungal infections		
Fluoxetine, fluvoxamine	Depression		
Ritonavir, cobicistat	Human immunodeficiency virus (HIV)		
Grapefruit juice			

R WHEN SHOULD I SEEK MEDICAL ATTENTION?

Tell any healthcare professional who sees you if any side effects occur while taking mavacamten, even those not discussed in this **Patient Guide**. Possible side effects and details of how to report them are also provided in the package leaflet. Reporting side effects to the MHRA helps collect additional safety information on this medicine.

Tell your prescriber or doctor, or seek other medical attention **immediately** if you experience new or worsening symptoms of heart failure, including shortness of breath, chest pain, fatigue, a racing heart (palpitations), or leg swelling.




If you have any questions or concerns regarding mavacamten, please discuss them with your prescriber, doctor, pharmacist or any member of your healthcare team.

For further information, please contact:

Telephone: 0800 731 1736

Email: medical.information@bms.com







© 2023 MyoKardia, Inc., a Bristol Myers Squibb company. Date of MHRA Approval: July 2023 Local Approval Number: 3500-GB-2200049, July 2023 3500-GL-2300005 02/23